Merus N.V.
NASDAQ: MRUS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jan van de Winkel
- Employees
- 260
- Headquarters
- Utrecht, Netherlands
- IPO year
- 2016
- Market cap
- $6.8B
- Website
- https://www.merus.nl
Loading MRUS…
Loading profile data…Frequently asked questions about MRUS
What does Merus N.V. (MRUS) do?
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoin...
Where does MRUS trade?
Merus N.V. (MRUS) trades on the NASDAQ Global Market.
What sector is MRUS in?
Merus N.V. (MRUS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Merus N.V.?
Jan van de Winkel is the chief executive officer of Merus N.V. (MRUS).
Where is Merus N.V. headquartered?
Merus N.V. is headquartered in Netherlands.
Does MRUS pay a dividend?
Merus N.V. (MRUS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MRUS go public?
Merus N.V. (MRUS) completed its initial public offering in 2016.